ICH consults on revised post-approval safety guideline that accounts for digital platforms
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyGlobalPharmaceuticalsRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyGlobalPharmaceuticals